A Safety and Tolerability Study of Jaktinib

Status unconfirmed · Phase 1

Conditions studied: Myelofibrosis

In brief

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

Key facts

Study ID

NCT05279001

Run by

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

People needed

26

Starts

2024-07-01

Expected to finish

2025-11-30

Last updated by the study team

2024-03-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of myelofibrosis (primary, post-polycythemia vera, or post-essential thrombocythemia).
• Relapsed/refractory to a marketed (FDA approved) JAK inhibitor.
• At least 18 years of age.
• ECOG PS 0, 1, or 2.
• Expected life expectancy is greater than 24 weeks.

You may not qualify if…

• Any chemotherapy, immunomodulatory therapy, immunosuppressive therapy, corticosteroids, or growth factor treatment within 14 days prior to initiation of study drug.
• Major surgery or radiation therapy within 28 days prior to initiation of study drug.
• With suspected allergies to jaktinib or its excipient.
• Another clinical trial of a new drug or medical instrument within 3 months before screening.
• Females who are pregnant, currently breastfeeding, planning to become pregnant.
• Unable to adopt effective contraceptive methods during the study.

Where it is running

• Site 01 — Canton, Ohio, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.